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rn).Summary The actual burden of chronic obstructive pulmonary disease (COPD) in
terms of health care use and costs strongly depends on the distribution of disease
severity. For the Netherlands, the distribution of diagnosed COPD was estimated by
classifying all patients with a physician diagnosis of COPD from two different sources
of general practitioners (GP)-data into mild (27%), moderate (55%), severe (15%) or
very severe COPD (3%) based on their post-bronchodilator FEV1% predicted,
according to the GOLD-guidelines. This distribution will most likely shift to the less
severe stages when under-reporting and under-diagnosis are reduced.
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Worldwide, chronic obstructive pulmonary disease
(COPD) causes serious health problems and dis-
ability. Models that project the future morbidity,
mortality and costs of COPD show that the burden
of COPD will increase during the next few dec-
ades.1,2 The actual burden in terms of costs stronglyed.
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population, as there is a powerful association
between use of healthcare services and disease
severity.3–5 To project the future burden of COPD by
disease severity and to evaluate the impact of
different smoking cessation interventions for pa-
tients with COPD on the burden of COPD in the
Netherlands, we have developed a population model
that simulates disease progression over time accord-
ing to severity stages.6 To classify the prevalence of
diagnosed COPD in the starting year of the simula-
tion over the stages mild, moderate, severe and very
severe COPD,7 it was necessary to know the
distribution of COPD disease severity in the Dutch
population of diagnosed COPD patients. Such data
have not been reported in the literature before and
are not routinely collected as part of any ongoing
data registration. Because in the Netherlands
virtually all people are registered with a general
practice (GP), the prevalence of diagnosed COPD is
generally derived from GP databases. This study
aimed to assess the severity distribution of COPD
from GP databases in the Netherlands.Methods
Two different sources of GP data were used. The
first data source contained all patients with
physician-diagnosed COPD including those with co-
existing asthma from five GP registrations in the
Nijmegen Monitoring Project (NMP).8 These prac-
tices are part of the academic GP network of the
University Medical Centre Nijmegen. In these
practices, all patients with COPD are coded using
International Classification of Primary Care9 codings
(R91/R95) and all available spirometric test results
are stored electronically.
The second data source was a clinical trial that
contained lung function data on COPD and asthma
patients from 25 GP practices in the Amsterdam
area.10 All registered patients with a diagnosis of
either COPD or asthma were asked to participate in
the trial. To be enrolled in the trial, participants
had to meet the following inclusion criteria: age
16–75 years, capable of filling in a Dutch ques-
tionnaire, no specific pulmonary disease other than
COPD or asthma and absence of any disease in a
terminal phase. Known asthma patients were
excluded from the dataset. All patients with
physician-diagnosed COPD (including COPD with
coexisting asthma) and patients for which the
exact GP diagnosis for the respiratory condition
was unknown entered our analysis. For the latter
group, the final decision whether or not patients
had COPD was based on lung function indices.For both datasets the classification of COPD
severity was based on post-bronchodilator FEV1%
predicted according to the class boundaries in the
GOLD classification.7 FEV1% predicted was calcu-
lated using ECCS/ ERS equations.11 Patients aged
o45 years were excluded.
For all NMP patients with a FEV1/FVC ratioo70%,
the largest FEV1% predicted value of the two most
recent consecutive years with measurements in the
period 1997–2002 was used for classification. When
post-bronchodilator values were not available, pre-
bronchodilator values were multiplied by 1.095.
This factor was based on the observed difference
between pre- and post-bronchodilator values from
NMP patients for whom both values were available
(62%). All patients from the Amsterdam data with a
FEV1/FVC ratio o70% were classified based on the
baseline lung function measurements of the clinical
trial performed in the period 1995–1998.Results
Study populations
In the NMP practices 530 patients had physician-
diagnosed COPD. For 307 (58%) of them sufficient
spirometric data were available. Patients with and
without spirometry did not differ with respect to
gender, age, co-morbid conditions and number of
drug prescriptions for COPD. Eighty-five patients
were excluded from further analyses because their
FEV1/FVC ratio was 470%. Six additional patients
were excluded because they were agedo45 years.
The remaining 216 patients (70% male) with a mean
age of 67.7 years were classified according to the
GOLD stages mild, moderate, severe and very
severe COPD. In the Amsterdam data, 1325 (65%)
of the 2047 patients, who met the inclusion
criteria, were willing to participate. Patients who
did not enter the clinical trial were significantly
younger and a higher percentage was male.10 A
total of 1308 patients had valid lung function
measurements at baseline. From this group 607
patients with a diagnosis of asthma only, 400
patients with a FEV1/FVC ratio 470% and 36
patients aged o45 years were excluded. In total,
265 COPD patients (65% male) with a mean age of
63.8 years remained for classification.
COPD severity distribution
Table 1 shows the results of the severity classifica-
tion based on GOLD stages for both data sources
separately as well as for both patient groups
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Table 1 Distribution of disease severity among COPD patients known to the GP. Classification is based on post-
bronchodilator FEV1.
COPD severity by GOLD criteria, FEV1/FVCo70%, percentage (95%-confidence interval)
GOLD I GOLD II GOLD III GOLD IV
Mild: FEV1%
predicted X80%
Moderate: 50pFEV1%
predicted o80%
Severe: 30pFEV1%
predicted o50%
Very severe: FEV1%
predicted o30%
NMP (%) 31 47 19 3
Amsterdam (%) 28 55 15 2
Total (%) 30 (26–34) 52 (47–56) 17 (13–20) 2 (1–4)
FEV1: Forced expiratory volume in 1 s.
FVC: Forced vital capacity.
Severity distribution of COPD in Dutch general practice 85combined. Figure 1 shows the frequency distribu-
tion of FEV1% predicted for the combined data. The
bars show the empirical data, the continuous line
the fitted normal distribution density function.
Statistical testing demonstrated that the empirical
data did not significantly deviate from a normal
distribution with a mean FEV1% predicted of 68.3
and a standard deviation of 19.9. For our simulation
model we based the severity distribution on this
normal distribution, truncated at 10 and 110 FEV1%
predicted: mild COPD 27%, moderate COPD 55%,
severe COPD 15% and very severe COPD 3%.Figure 1 Frequency distribution of FEV1% predicted of
prevalent, diagnosed cases of COPD (n ¼ 481), defined as
FEV1/FVCo70%, based on the combined data sources.Discussion
This study showed that in the Netherlands, in total,
80% of the patients with a physician diagnosis of
COPD had mild or moderate disease whereas almost
20% had severe or very severe COPD. As virtually all
people in the Netherlands, including those treated
by pulmonologists, are registered with a GP
practice, these data probably represent the popu-
lation of physician-diagnosed COPD patients fairly
well. It does not reflect the COPD severity
distribution in the entire Dutch community, as
under-presentation and under-diagnosis is not
accounted for.
Some of the patients also had a diagnosis of
asthma. They were included. Excluding these
patients has little impact; the proportion of
patients with severe and very severe COPD changes
from 19% to 22%.
The five NMP practices are known for keeping
electronic records of spirometric test results.
Nevertheless, spirometric data were absent in the
electronic records for almost 40% of the patients
with a physician diagnosis of COPD. Although no
significant differences were found between thegroups with and without spirometry on general
characteristics, the lack of lung function data may
have influenced the results. In the Amsterdam
database the COPD and asthma patients who
participated in the clinical trial were not comple-
tely representative of the total population of COPD
and asthma patients in the 25 GP practices.
Patients who refused to participate were signifi-
cantly younger and a higher percentage was male.
Whether this has influenced our results and to what
extent is difficult to determine.
An interesting finding was that 32% of the patients
with a physician diagnosis of COPD did not meet the
criterion of airflow limitation as it is defined in the
GOLD-guidelines (i.e., FEV1/FVC ratio o70%). This
indicates that in quite a few cases physicians do not
base their diagnosis on lung function, but on criteria
such as a history of smoking combined with chronic
cough and dyspnoea over prolonged periods of time.
As the systemic effects of COPD are increasingly
recognized, it is likely that in the future COPD
severity will be based on a combination of variables,
like the recently published BODE-index, which
combines FEV1% predicted, dyspnoea score, 6-min
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M. Hoogendoorn et al.86walk distance and body mass index.12 However, as
this is only a recent development, no routine
registrations exist that generate these data for
epidemiological use yet.References
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